Ground Swell Capital’s Rocket Pharmaceuticals RCKT Stock Holding History

Ground Swell Capital’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,001	Closed	-$50.1K	–	209
2026 Q1	$50.1K	Buy	+14,001	New	+$55.6K	0.1%	81

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ground Swell Capital's RCKT Position: Q2 2026 in Review

Ground Swell Capital sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 14,001 shares — an estimated $50.1K sold.

Ground Swell Capital first reported a position in RCKT in Q1 2026 and held it in 1 quarter. The position peaked at $50.1K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Ground Swell Capital reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ground Swell Capital sold 14,001 Rocket Pharmaceuticals shares in Q2 2026, an estimated $50.1K.
Ground Swell Capital first reported a position in Rocket Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Ground Swell Capital's Rocket Pharmaceuticals position peaked at $50.1K in Q1 2026.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Ground Swell Capital's 13F filing for Q2 2026, filed 5 Aug 2026.